• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
Grand Rounds

Results from the SPREE Trial: How Does First Trimester Preeclampsia Screening Compare to Current Guidelines?

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Current NICE guidelines use maternal characteristics and medical history to identify women at high risk for preeclampsia (PE) who could benefit from aspirin
  • NICE guideline considers a pregnant woman at high risk if
    • Any one major factor
      • History of hypertensive disease in previous pregnancy
      • Chronic kidney disease
      • Autoimmune disease
      • Diabetes mellitus
      • Chronic hypertension
    • OR any two moderate factors
      • First pregnancy at age ≥ 40 years
      • Interpregnancy interval > 10 years
      • BMI at first visit ≥ 35 kg/m2
      • Family history of PE
    • Using more traditional approach of professional committees, each factor is considered separately
    • Tan et al. (Ultrasound in Obstetrics & Gynecology, 2018) compared the above NICE approach to screening PE to a method that uses Bayes’ theorem that combines maternal factors with biomarkers

METHODS:

  • Prospective multicenter cohort study
  • Screening program for pre-eclampsia (SPREE) study
  • Participants: Singleton pregnancies at 11–13 weeks’ gestation had recording of maternal characteristics and medical history and measurements of
    • Mean arterial pressure (MAP)
    • Uterine artery pulsatility index (UtA‐PI)
    • Serum placental growth factor (PlGF)
    • Serum pregnancy‐associated plasma protein‐A (PAPP‐A)
  • The performance of screening for PE by the Bayes’ theorem‐based method was compared with that of the NICE method
  • Primary outcome
    • Detection rate (DR) using NICE method vs mini‐combined test (maternal factors, MAP and PAPP‐A) in the prediction of PE at any gestational age (all‐PE) for the same screen‐positive rate determined by the NICE method
  • Secondary comparisons
    • DR of screening recommended by the NICE guidelines vs 3 Bayes’ theorem‐based methods for prediction of preterm PE (requiring delivery <37weeks)
      • Maternal factors, MAP and PAPP‐A
      • Maternal factors, MAP and PlGF
      • Maternal factors, MAP, UtA‐PI and PlGF

RESULTS:

  • 17,051 women were eligible and outcome data were obtained from 16,747
  • All-PE developed in 2.8% of the 16,747 pregnancies and preterm PE developed in 0.8%
  • NICE method for PE
    • Screen positive rate: 10.3%
    • DR for all‐PE: 30.4%
    • DR for preterm PE: 40.8%
    • There was only 23% compliance with aspirin recommendation
  • Mini-combined method for PE
    • DR of the mini‐combined test for all‐PE was 42.5%
    • Superior to that of the NICE method by 12.1% (95% CI, 7.9–16.2%)
  • Screening for preterm PE compared to NICE
    • Maternal factors, MAP and PlGF: DR was 69.0%, which was superior to NICE method by 28.2% (95% CI, 19.4–37.0%)
    • Maternal factors, MAP, UtA‐PI and PlGF: DR was 82.4%, which was to NICE method by 41.6% (95% CI, 33.2–49.9%)

CONCLUSION:

  • NICE detection rates and compliance were lower than using a Bayesian approach that incorporates serum markers
  • The authors state that a PE methodology that combines biomarkers with maternal factors is a substantial improvement over current recommendations

Learn More – Primary Sources:

Comparison of diagnostic accuracy of early screening for pre‐eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE

Fetal Medicine Foundation Preeclampsia Risk Calculator

image_pdfFavoriteLoadingFavorite

< Previous
All Grand Rounds Posts
Next >

Related ObG Topics:

Aspirin Treatment for Women at Risk for Preeclampsia – ACOG, SMFM and USPSTF Recommendations
ASPRE Trial: A Combined Risk Algorithm and Use of Aspirin to Prevent Preterm Preeclampsia
Which Markers Can We Use to Screen for Early and Late Preeclampsia?
Diagnosing Preeclampsia – Key Definitions and ACOG Guidelines

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site